Previous close | 167.25 |
Open | 166.64 |
Bid | 164.11 x 100 |
Ask | 164.26 x 100 |
Day's range | 160.38 - 166.64 |
52-week range | 125.82 - 335.91 |
Volume | |
Avg. volume | 869,170 |
Market cap | 11.711B |
Beta (5Y monthly) | 1.00 |
PE ratio (TTM) | 56.81 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Strong global new customer starts fueled by the ongoing Omnipod 5 demand are expected to significantly benefit Insulet's (PODD) first-quarter performance.
We have narrowed our search to five S&P 500 medical stocks that are poised to beat on first-quarter earnings results.These are: HCA, UHS, LH, EW, PODD.